Show simple item record

 
dc.contributorVall d'Hebron Barcelona Hospital Campus
dc.contributor.authorHernando Cubero, Jorge
dc.contributor.authorAlonso, Lola
dc.contributor.authorFasani, Roberta
dc.contributor.authorJiménez Flores, José Antonio
dc.contributor.authorElez Fernandez, Mª Elena
dc.contributor.authorTabernero Caturla, Josep
dc.contributor.authorNuciforo, Paolo Giovanni
dc.contributor.authorCapdevila Castillon, Jaume
dc.contributor.authorLandolfi, Stefania
dc.contributor.authorComas Navarro, Raquel
dc.contributor.authorRuiz Pace, Fiorella
dc.contributor.authorSerna, Garazi
dc.contributor.authorDienstmann, Rodrigo
dc.date.accessioned2021-10-04T12:58:49Z
dc.date.available2021-10-04T12:58:49Z
dc.date.issued2020-10
dc.identifier.citationSerna G, Ruiz-Pace F, Hernando J, Alonso L, Fasani R, Landolfi S, et al. Fusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer. Ann Oncol. 2020 Oct;31(10):1366–75.
dc.identifier.issn0923-7534
dc.identifier.urihttps://hdl.handle.net/11351/6378
dc.descriptionFusobacterium nucleatum; Locally advanced rectal cancer; Preoperative chemoradiotherapy
dc.description.abstractBackground Accumulating evidence has identified Fusobacterium as an important pathogenic gut bacterium associated with colorectal cancer. Nevertheless, only limited data exist about the role of this bacterium in locally advanced rectal cancer (LARC). In this study, we quantified Fusobacterium nucleatum in untreated and post-neoadjuvant chemoradiotherapy (nCRT) samples from LARC patients and investigated its association with therapy response and survival. Patients and methods A total of 254 samples from 143 patients with rectal adenocarcinomas were analyzed for the presence and abundance of F. nucleatum using RNA in situ hybridization and digital image analysis. Assay accuracy was determined using infected cell lines and tumor samples with available quantitative PCR data. We studied the impact of F. nucleatum load on pathologic complete response and relapse-free survival. Treatment-induced changes were evaluated in paired pre- and post-nCRT samples (n = 71). Finally, tumor microenvironment changes during nCRT were assessed in paired samples (n = 45) by immune contexture analysis. Results F. nucleatum tissue levels by RNA in situ hybridization strongly correlated with quantitative PCR (r = 0.804, P < 0.001). F. nucleatum abundance was higher in untreated [median, 7.4; 95% confidence interval (3.7–16.2)] compared with treated [median, 1.6; 95% confidence interval (1.3–2.4)] tumors (P <0.001) with 58% (73/126) and 26% (22/85) positive tumors, respectively (P < 0.001). Baseline F. nucleatum levels were not associated with pathologic complete response. F. nucleatum positivity after nCRT, but not baseline status, significantly increased risk of relapse [hazard ratio = 7.5, 95% confidence interval (3.0–19.0); P < 0.001]. Tumors that turned F. nucleatum-negative after nCRT had a strong increase in CD8+ T cells post-nCRT (P < 0.001), while those that persisted F. nucleatum-positive after nCRT lacked CD8+ T cells induction in post-nCRT samples compared with baseline (P = 0.69). Conclusion F. nucleatum persistence post-nCRT is associated with high relapse rates in LARC, potentially linked to suppression of immune cytotoxicity.
dc.language.isoeng
dc.publisherElsevier
dc.relation.ispartofseriesAnnals of Oncology;31(10)
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.sourceScientia
dc.subjectBacteris gramnegatius
dc.subjectRecte - Càncer - Quimioteràpia
dc.subjectRecte - Càncer - Radioteràpia
dc.subject.meshRectal Neoplasms
dc.subject.meshFusobacterium nucleatum
dc.subject.meshChemoradiotherapy
dc.titleFusobacterium nucleatum persistence and risk of recurrence after preoperative treatment in locally advanced rectal cancer
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1016/j.annonc.2020.06.003
dc.subject.decsneoplasias del recto
dc.subject.decsFusobacterium nucleatum
dc.subject.decsquimiorradioterapia
dc.relation.publishversionhttps://doi.org/10.1016/j.annonc.2020.06.003
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.organismesInstitut Català de la Salut
dc.contributor.authoraffiliation[Serna G, Alonso L, Fasani R, Jimenez J, Nuciforo P] Molecular Oncology Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Ruiz-Pace F, Comas R, Dienstmann R] Oncology Data Science Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Hernando J, Elez E, Capdevila J] Servei d’Oncologia Mèdica, Unitat de Tumors gastrointestinals i endocrins, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Landolfi S] Servei d’Anatomia Patològica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d'Hebron Hospital Universitari, Barcelona, Spain. Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. IOB-Quiron, UVic-UCC, Barcelona, Spain
dc.identifier.pmid32569727
dc.identifier.wos000574680100001
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record